Imipenem E Cilastatina Hikma Farmacêutica

Imipenem and Cilastatin, the active ingredient in Imipenem E Cilastatina Hikma Farmacêutica, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft tissue infections, febrile neutropenia, and both community‑acquired and hospital‑acquired pneumonia in hospitalized patients.

GNH USA supplies Imipenem E Cilastatina Hikma Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imipenem and Cilastatin is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections. - Complicated intra‑abdominal infections: effective bacterial eradication in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: clears resistant uropathogens in complicated cases. - Skin and soft tissue infections: treats severe cellulitis and deep tissue infections. - Febrile neutropenia: provides rapid coverage against gram‑negative organisms. - Community‑acquired and hospital‑acquired pneumonia: combats resistant respiratory pathogens.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Infusion site reactions: erythema, pain or phlebitis at the injection site. - Elevated liver enzymes: transient increase in hepatic transaminases. - Rash: mild maculopapular eruptions.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated diarrhea that can be severe. - Renal toxicity: acute kidney injury in susceptible individuals. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare severe skin reactions. - Neutropenia: marked reduction in white blood cell count.

Imipenem and Cilastatin requires careful patient assessment and monitoring. - Renal function: assess creatinine clearance before initiating therapy. - Seizure risk: avoid or use with caution in patients with a history of seizures or CNS disorders. - Allergy: screen for β‑lactam hypersensitivity before administration. - Drug interactions: review concomitant medications that may lower seizure threshold. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem and Cilastatin can interact with several medications, requiring clinical vigilance. Major Interactions (Avoid): - Valproic acid: may reduce serum levels and increase seizure risk. - Cisplatin: combined use can heighten nephrotoxicity. - Other carbapenems: concurrent use may increase toxicity without added benefit. Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Aminoglycosides: increased risk of nephrotoxicity; assess kidney parameters. - Warfarin: may alter INR; monitor coagulation status.